Tenaya Therapeutics logo
Tenaya Therapeutics
TNYA | NASDAQ
Chart Builder DCF Calculator
$0.39
-$0.13 (-25.14%)
At close: Oct 14, 2026, 4:00 PM ET

Tenaya Therapeutics Company Profile

Company profile explained

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Executives

Name Position
Faraz Ali President, CEO & Director
Kee-Hong Kim Chief Technology Officer
Benoit G. Bruneau Scientific Founder
Bruce R. Conklin Scientific Founder
Deepak Srivastava Scientific Founder, Chairman of Scientific Advisory Board & Director
Eric Hyllengren CFO & Principal Accounting Officer
Eric N. Olson Scientific Founder & Member of Scientific Advisory Board
Saptarsi Haldar Scientific Founder
Sheng Ding Scientific Founder
Whittemore G. Tingley Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 11, 2026 4 Filing
Sep 11, 2026 4 Filing
Aug 24, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 05, 2026 S-8 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 14, 2026 3 Filing
Jul 14, 2026 4 Filing
View All SEC Filings ➞
Tenaya Therapeutics
Tenaya Therapeutics logo
Country United States
IPO Date Jul 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 70
CEO Faraz Ali

Contact Details

171 Oyster Point Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol TNYA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001858848
CUSIP Number 87990A106
ISIN Number US87990A1060
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.